AltPep
Todd Patrick is the former CEO of Armata Pharmaceuticals (NYSE American: ARMP). Todd led the May 2019 merger of Armata’s two predecessor companies – C3J Therapeutics, where he was the President and CEO since 2010, and AmpliPhi Biosciences to create Armata. Todd earlier served as President and COO of ID Biomedical Corporation (IDB). Under his leadership, IDB grew to become the second largest influenza vaccine producer in North America prior to its acquisition by GlaxoSmithKline for $1.7 billion in 2005. In addition to AltPep and Armata, Todd is on the Board of CRH Medical Corporation (NYSE: CRHM) and the non-profit Foster Foundation.
This person is not in the org chart
This person is not in any offices
AltPep
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. They are currently focusing on CNS disorders, in particular Alzheimer’s Disease (AD). They target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).